Results 201 to 210 of about 21,331 (238)
Some of the next articles are maybe not open access.
The role of noncovalent BTK inhibitors in the era of covalent BTK inhibitors.
Clinical advances in hematology & oncology : H&ODespite significantly improving outcomes in patients with B-cell malignancies, covalent Bruton tyrosine kinase (BTK) inhibitors are limited by toxicities and the development of resistance. Some toxicities can be life-threatening, such as cardiotoxicity.
Fateeha, Furqan, Nirav N, Shah
openaire +1 more source
Pirtobrutinib shows evidence to inaugurate a third generation of BTK inhibitors
Lancet, The, 2021Vincent Ribrag
exaly
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
International Journal of Molecular Sciences, 2021Chiara Brullo, Carla Villa, Bruno Tasso
exaly
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies
Archives of Pharmacal ResearchBruton's tyrosine kinase (BTK) is a therapeutically validated drug target. Small-molecule inhibitors of BTK have changed the treatment paradigms of multiple B-cell malignancies and evolved over three generations to overcome clinical challenges. Four drugs are now approved by the FDA, including the first-in-class drug ibrutinib and successively approved
openaire +2 more sources
BTK Inhibitors and Chemoimmunotherapy for CLL
Clinical Lymphoma Myeloma and Leukemia, 2020openaire +2 more sources
Recent development of BTK-based dual inhibitors in the treatment of cancers
European Journal of Medicinal Chemistry, 2022Chi Meng, Dezhi Yang, Jianqiang Qian
exaly
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
Frontiers in Immunology, 2021Marzia Palma +2 more
exaly